The organoid breakthrough pushing research toward real drug impact
25 Feb 2026
Organoids are transforming how researchers build human‑relevant disease models, especially when animal systems can’t capture key biology. Partnering with LICORbio has helped one lab better protect these sensitive structures by minimizing time outside the incubator and enabling high‑quality, multi‑scale 3D imaging with the LICORbio Atlas™ Imaging System. In this SelectScience interview, Dr. Rodrigo Cristofoletti, Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida, shares how these advances are accelerating organoid research and why he’s excited about the field’s shift from academic innovation to real‑world drug development.
This video was filmed at SLAS 2026.
About the company
LICORbio
LICORbio, a brand of LI-COR Biosciences, develops state-of-the-art imaging systems integrated with dedicated reagents, powerful software, and unmatched support to ensure scientists obtain reliable, quantitative research results. With over 100,000 citations in peer-reviewed publications, these solutions help to improve lives by advancing discovery with speed, accuracy, and consistency. LICORbio continually strives to improve the human condition through innovative research tools that enable scientists to solve the challenges that face humanity. LICORbio is ISO 9001:2015 certified. Learn more at licorbio.com.
Related products
Request Quote for All Products
LICORbio Atlas™ Imaging System
LICORbioThe LICORbio Atlas Imaging System is the first solution purpose-built for both 2D and 3D assays, delivering higher-content, higher-throughput imaging with unmatched speed, scale, clarity, and ease. This single platform simplifies workflows, eliminates inefficiencies, and captures deep spatial insights. All in a fraction of the time—and at a fraction of the cost—of competitive solutions.
